Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.66 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.65 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.65 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.65 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.65 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.61 |
| ▸ | DHFR | P00374 | 11/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | TLR4 | O00206 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | TYMS | P04818 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.66 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3171572 | 0.99 | DHFR (0.69) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL221621 | 0.99 | DHFR (0.71) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL29658170 | 0.99 | DHFR (0.71) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL30110296 | 0.91 | DHFR (0.62) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL11913611 | 0.90 | DHFR (0.71) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL13985918 | 0.90 | DHFR (0.71) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL13529957 | 0.90 | DHFR (0.60) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL10379252 | 0.89 | DHFR (0.59) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL14753789 | 0.88 | DHFR (0.66) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL22201137 | 0.87 | HDAC4 (0.70) | DHFRKDM4ETLR4MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7881871-B2 | Method for designing surfaces | BIO-LAYER PTY LIMITED (AU) | 2011-02-01 | — | — | US | claimed |
| EP-1700244-A4 | A METHOD FOR DESIGNING SURFACES | BIO LAYER PTY LTD (AU) | 2009-07-08 | — | — | EP | claimed |
| US-20070099235-A1 | Method for designing surfaces | BIO-LAYER PTY LIMITED (AU) | 2007-05-03 | — | — | US | claimed |
| EP-1700244-A1 | A METHOD FOR DESIGNING SURFACES | Bio-Layer Pty Limited (AU) | 2006-09-13 | — | — | EP | claimed |
| WO-2005057462-A1 | A METHOD FOR DESIGNING SURFACES | BIO-LAYER PTY LIMITED (AU) | 2005-06-23 | — | — | WO | claimed |
| US-7881871-B2 | Method for designing surfaces | BIO-LAYER PTY LIMITED (AU) | 2011-02-01 | — | — | US | disclosed |
| EP-1700244-A4 | A METHOD FOR DESIGNING SURFACES | BIO LAYER PTY LTD (AU) | 2009-07-08 | — | — | EP | disclosed |
| US-20080090847-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | PLIVA D.D. (HR) | 2008-04-17 | — | — | US | disclosed |
| US-7345048-B2 | Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors | PLIVA D.D. (HR) | 2008-03-18 | — | — | US | disclosed |
| US-20070099235-A1 | Method for designing surfaces | BIO-LAYER PTY LIMITED (AU) | 2007-05-03 | — | — | US | disclosed |
| EP-1700244-A1 | A METHOD FOR DESIGNING SURFACES | Bio-Layer Pty Limited (AU) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005057462-A1 | A METHOD FOR DESIGNING SURFACES | BIO-LAYER PTY LIMITED (AU) | 2005-06-23 | — | — | WO | disclosed |
| EP-1411949-A4 | 8/17 HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | ESSENTIAL THERAPEUTICS INC (US) | 2004-11-24 | — | — | EP | disclosed |
| EP-1411949-A2 | 8/17 HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | Essential Therapeutics, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030181470-A1 | Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors | ESSENTIAL THERAPEUTICS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003001887-A2 | FUSED PYRIMIDINES AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | ESSENTIAL THERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| EP-0728018-A1 | THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995013095-A2 | THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181470-A1 | Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors | AAAS, ALAD, NAALAD2 | GLA 491/4885HDAC4 3390/4885HDAC7 2330/4885 |
| US-20080090847-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | AAAS, ALAD, NAALAD2 | GLA 491/4885HDAC4 3390/4885HDAC7 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.